Unassociated Document
   
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): April 9, 2008
 
 
NEKTAR THERAPEUTICS
(Exact name of Registrant as specified in its charter)
 
Delaware
 
0-24006
 
94-3134940
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
 
201 Industrial Road
San Carlos, California 94070
(Address of principal executive offices and Zip Code)
 
Registrant’s telephone number, including area code: (650) 631-3100
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
 
Item 8.01
 
Other Events.
 
 
On April 9, 2008, Nektar Therapeutics issued the press release which is filed herewith as Exhibit 99.1 to the report.
 
 
 
Item 9.01
 
Financial Statements and Exhibits
     
Item No.
  
Description
     
99.1
  
Press Release titled “Nektar Terminates All Negotiations with Potential Partners for Inhaled Insulin: Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients.”
 
 
 
 
 
SIGNATURES
 
Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
   
By:
 
/s/ Gil M. Labrucherie
 
 
Gil M. Labrucherie
 
 
General Counsel and Secretary
   
Date:
April 9, 2008